Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
EPC1 antisense RNA 2 (EPC1-AS2) is a long non-coding RNA (lncRNA) transcribed antisense to the EPC1 gene. There is currently no evidence that EPC1-AS2 encodes a protein or acts as a conventional druggable therapeutic target such as a receptor, enzyme, transporter, or transcription factor. Its precise biological function, involvement in disease, or role as a biomarker is not characterized in the scientific literature[3]. The main gene (EPC1) it is antisense to plays a role in epigenetic regulation and cancer biology, but EPC1-AS2 itself is not an established therapeutic or diagnostic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on EPC1 antisense RNA 2 (EPC1-AS2).